Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| SHPG | Shire PLC Sponsored ADR | 0.24% | 178.58 | 0.4% | $137.09m | |
| PRGO | Perrigo Co. Plc | 0.48% | 73.34 | 6.8% | $93.10m | |
| JAZZ | Jazz Pharmaceuticals Plc | 0.68% | 163.03 | 2.2% | $71.22m | |
| MNK | Mallinckrodt Plc | -0.40% | 29.67 | 21.1% | $65.61m | |
| ENDP | Endo International Plc | 0.13% | 15.96 | 8.9% | $57.71m | |
| GWPH | GW Pharmaceuticals PLC Sponsored ADR | 2.98% | 153.64 | 6.8% | $51.91m | |
| PTLA | Portola Pharmaceuticals, Inc. | 1.31% | 28.63 | 7.7% | $39.01m | |
| UTHR | United Therapeutics Corporation | -0.27% | 125.86 | 14.4% | $38.69m | |
| SAGE | SAGE Therapeutics, Inc. | -1.45% | 144.83 | 9.6% | $36.37m | |
| CTLT | Catalent Inc | -0.33% | 42.74 | 2.4% | $36.15m | |
| ICPT | Intercept Pharmaceuticals, Inc. | -1.03% | 119.36 | 18.7% | $32.09m | |
| SUPN | Supernus Pharmaceuticals, Inc. | 2.13% | 47.90 | 6.2% | $28.67m | |
| PCRX | Pacira Pharmaceuticals, Inc. | 7.32% | 51.35 | 10.6% | $27.64m | |
| ZGNX | Zogenix, Inc. | -3.29% | 47.05 | 10.0% | $27.47m | |
| MDCO | Medicines Company | -0.18% | 33.60 | 21.8% | $24.49m |
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development of the liver targeted stearoyl-coenzyme A desaturase-1 modulator Aramchol, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. The Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.